Immersion Investment Partners, LP on Strata Critical Medical
Thesis
Immersion sees Strata as an overlooked remainco created after the former Blade sold its passenger e-mobility operation and retained its organ-transplant logistics and clinical-services business. Strata has grown rapidly, operates across a fragmented transplant-services industry and holds meaningful shares in organ placement, recovery, air logistics and ground logistics. Structural growth is being driven by longer organ-transport distances, a larger donor pool and rapid adoption of normothermic regional perfusion, where Strata is a leading provider. The company also has no debt and a strong balance sheet that can support consolidation of smaller competitors. Immersion expects low-teens organic growth and believes acquisitions and scale can drive EBITDA growth above 30% annually over the next five years. At the approximately $5 share price discussed in the letter, the fund believes it is paying less than three times estimated 2030 EBITDA and could earn five to eight times its investment if the thesis is correct.
“If we are correct, we will earn five to eight times our investment in the stock.”
Key risks
- The growth thesis depends on continued adoption of NRP procedures and longer organ-transport distances.
- The company is pursuing an active acquisition strategy that introduces integration and execution risk.
- Expected margin expansion depends on achieving greater scale.